Lupus (SLE): vizsgálatok itt: Franciaország

In Franciaország 51 Also abroad 354

51 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.

3. fázisTaking people
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
Where
Clermont-Ferrand, Lyon, Marseille, Paris, Pessac, Saint-Denis, Saint-Pierre, Toulon, Tours, Vandœuvre-lès-Nancy
Életkor
18 év to 70 év
People
245 worldwide
Run by
AstraZeneca
See details and how to joinNCT07430306
3. fázisTaking people
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
Where
Bordeaux, Nantes, Paris, Poitiers, Rennes, Strasbourg, Toulouse
Életkor
5 év to 80 év
People
1072 worldwide
Run by
AstraZeneca
See details and how to joinNCT07691970
3. fázisTaking people
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
Where
Montpellier, Paris, Paris Cedex 13, Toulouse, Toulouse Cedex 9, Tours Cedex 9
Életkor
12 év to 100 év
People
550 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06133972 · EU 2023-505929-14-00
3. fázisTaking people
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
Where
Besancon Cedex, Bordeaux, Grenoble Cedex 9, Marseille, Poitiers, Toulouse Cedex 9
Életkor
18 év to 100 év
People
348 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06711887 · EU 2024-515280-60-00
1. fázisTaking people
To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
Where
Lyon Cedex 03, Poitiers, Toulouse Cedex 9
Életkor
18 év to 75 év
People
46 worldwide
Run by
Genentech, Inc.
See details and how to joinNCT07629583 · EU 2025-522904-26-00
3. fázisTaking people
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
Where
Lille, Lyon, Paris Cedex 20, Rouen Cedex, St Etienne Cedex 2
Életkor
18 év to 75 év
People
202 worldwide
Run by
EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07332481 · EU 2025-523871-44-00
3. fázisTaking people
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
Where
Bordeaux Cedex, Clermont-Ferrand, Dijon, Paris, Pessac
Életkor
18 év to 75 év
People
202 worldwide
Run by
EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07355218 · EU 2025-524855-30-00
2. fázisTaking people
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
Where
Le Kremlin-Bicetre, Paris, Toulouse Cedex 9
Életkor
5 év to 17 év
People
40 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05039619 · EU 2023-505825-15-00
3. fázisTaking people
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
Where
Caen Cedex 9, Grenoble Cedex 9, Le Mans Cedex 9, Lyon Cedex 04, Paris, Toulouse Cedex 9
Életkor
18 év to 75 év
People
600 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07438496 · EU 2025-523552-31-00
3. fázisTaking people
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Where
Bordeaux, Le Kremlin-Bicetre, Le Mans Cedex 9, Montpellier Cedex 5, Paris, Strasbourg Cedex
Életkor
16 év and over
People
450 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT06617325 · EU 2023-508191-11-00
No phaseTaking people
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
Where
Bordeaux, Paris, Strasbourg
Életkor
16 év and over
People
223 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07175285
1/2. fázisNot yet taking people in Franciaország
Phase 1/2 study to evaluate the safety, pharmacokinetics, and preliminary efficacy of SAR447998 in adults with refractory Systemic Lupus Erythematosus or Rheumatoid Arthritis
Where
Marseille, Montpellier Cedex 5, Pessac
Életkor
18 év and over
People
10
Run by
Sanofi-Aventis Recherche & Developpement
See details and how to join2026-526117-28-00 · EU 2026-526117-28-00
1. fázisTaking people
Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
Where
Bordeaux
Életkor
18 év to 60 év
People
90 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06975787 · EU 2024-518288-37-00
3. fázisNot yet taking people in Franciaország
Rollover Study for Participants Who Have Completed a Previous Clinical Study with Anifrolumab (Saphnelo) and Clinically Beneﬁted from Continued Treatment.
Where
Bordeaux Cedex, Paris, Strasbourg Cedex 2, Toulouse Cedex 9
People
340 worldwide
Run by
AstraZeneca AB
See details and how to join2026-526419-13-00 · EU 2026-526419-13-00
1. fázisTaking people
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
Where
Nantes, St Etienne Cedex 2, Toulouse Cedex 9
Életkor
18 év to 70 év
People
24 worldwide
Run by
Cullinan Therapeutics Inc.
See details and how to joinNCT06613360 · EU 2024-518780-36-00
1. fázisTaking people
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
Where
Bordeaux, Montpellier, Nancy, Paris, Strasbourg Cedex 2, Toulouse Cedex 9
Életkor
18 év to 70 év
People
72 worldwide
Run by
AstraZeneca
See details and how to joinNCT06916806 · EU 2024-519015-34-00
3. fázisCsak meghívásos
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
Where
Bordeaux, Le Kremlin-Bicetre, Le Mans Cedex 9, Montpellier Cedex 5, Paris, Strasbourg Cedex
Életkor
16 év and over
People
760 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT04976322 · EU 2023-506368-14-00
1. fázisNot yet taking people in Franciaország
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
Where
Montpellier, Paris
Életkor
18 év and over
People
60 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07873931
1/2. fázisTaking people
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Where
Marseille Cedex 05, Paris, Paris Cedex 18, Poitiers
Életkor
12 év to 65 év
People
28 worldwide
Run by
Cabaletta Bio
See details and how to joinNCT06121297 · EU 2023-507613-10-01
3. fázisCsak meghívásos
A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)
Where
Bordeaux, Clermont-Ferrand, Montpellier
Életkor
18 év and over
People
864 worldwide
Run by
Biogen
See details and how to joinNCT05352919 · EU 2023-505635-13-00
2. fázisTaking people
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
Where
Le Kremlin-Bicêtre, Lille, Lyon, Lyon Cédex 3, Marseille, Paris, Strasbourg, Toulouse
Életkor
18 év to 75 év
People
220 worldwide
Run by
Amgen
See details and how to joinNCT06570798
3. fázisTaking people
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
Where
Clermont-Ferrand, Lyon Cedex 03, Marseille, Nancy, Paris, Saint-Pierre, St Denis, Talence, Toulon Cedex 9, Tours
Életkor
18 év and over
People
113 worldwide
Run by
AstraZeneca AB
See details and how to join2025-523670-17-00 · EU 2025-523670-17-00
3. fázisTaking people
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
Where
Bordeaux, Bron, Le Kremlin Bicetre Cedex, Lille, Toulouse Cedex 9
Életkor
5 év to 17 év
People
100 worldwide
Run by
AstraZeneca
See details and how to joinNCT05835310 · EU 2022-502289-25-00
3. fázisTaking people
Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-1)
Where
Le Kremlin Bicetre Cedex, Nantes, Strasbourg Cedex, Tours
Életkor
18 év and over
People
147 worldwide
Run by
Bristol-Myers Squibb Services Unlimited Company
See details and how to join2022-500699-76-00 · EU 2022-500699-76-00
No phaseTaking people
Anifrolumab Malignancy and Serious Infections Study
Where
Charenton-le-Pont
Életkor
18 év to 130 év
People
3506 worldwide
Run by
AstraZeneca
See details and how to joinNCT07000110